ABSTRACT
With the continuing development of clinical drug resistance among bacteria and the advent of resistance to the released agents quinupristin-dalfopristin and linezolid, the need for new, effective agents to treat multidrug resistant gram-positive infections remains important. With treatment options limited, it has become critical to identify antimicrobials with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives. This chapter focuses on agents recently introduced to the clinic and those presently in clinical development for the treatment of skin and skin structure infections (SSSIs). In addition, novel antifungal agents will be reviewed, as will novel dosing of antiviral agents for herpes labialis.
